It is now generally accepted that many of the known pharmacological effects of cannabinoids are mediated by receptors. These are CBI, that are expressed mainly by central and peripheral neurons, and CBz, that occur mainly in immune cells [1, 2] . The discovery of these receptors has prompted the development of selective CB, and CBz receptor agonists and antagonists [ 1 , 3 4 1 and has also led to the demonstration that there are endogenous agonists for these receptors in mammalian tissues [ 1, 2, . Cannabinoid receptors and their endogenous ligands together constitute what is referred to in this paper as 'the endogenous cannabinoid system'.
The most important of the endogenous cannabinoids discovered to date are arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol and there is evidence that both of these compounds serve as neuromodulators or neurotransmitters. This comes from demonstrations that they can be synthesized by neurons, that they can undergo depolarization-induced release from neurons and that, once released, they are rapidly removed from the extracellular space by tissue uptake processes andlor enzymic hydrolysis [1, 2, 10, 14, 15] . With regard to the biosynthesis of anandamide, there is growing evidence that this fatty acid amide is usually formed from 'V-arachidonoyl phosphatidylethanolamine (NAPE) by the action of a phospholipase D-like enzyme and that NAPE formation results from calcium-dependent, N-acyltransferase catalysed transfer of an arachdinonoyl group from the sn-1 position of phospholipids to the amino group of phosphatidylethanolamine [2, 10, 16, 17] . Removal of anandamide from the extracellular space seems to depend on a carrier-mediated, saturable 
uptake process present in neurons and glia [18] .
Once within the cell, anandamide is presumably hydrolysed to arachidonic acid and ethanolamine by fatty acid amide hydrolase. This is a microsoma1 enzyme, found both in neurons and in some non-neuronal tissues, that seems to serve as a general fatty acid amide hydrolase [2,11,13,14,16,19-2.51 . Human, rat and mouse fatty acid amide hydrolases have now been cloned [26, 27] . Arachidonic acid and ethanolamine can undergo enzymic condensation to form anandamide. However, in most tissue preparations the required concentrations of these two reactants (particularly of ethanolamine) are well above expected physiological levels [2] . The neuronal biosynthesis of 2-arachidonoyl glycerol seems to be catalysed by diacylglycerol lipase and to proceed from calcium-dependent hydrolysis of 1-acyl-2-arachidonoyl glycerols such as sn 1-stearoyl-2-arachidonoyl glycerol and sn1-arachidonoyl-2-arachidonoyl glycerol that are formed from phospholipids, probably by the action of phospholipase C [2, 9, 15, 28] . T h e involvement of other lipases in 2-arachidonoyl glycerol biosynthesis has not yet been excluded. Enzymic hydrolysis of 2-arachidonoyl glycerol has been detected in cytoplasmic and microsomal fractions of NIBTGZ mouse neuroblastoma cells [15] . The presence of a carrier-mediated uptake process for 2-arachidonoyl glycerol in neurons remains to be established. However, such a process has been detected in RBL-2H3 (basophilic) cells [29] .
Although the detailed biochemistry, physiology and pathophysiology of the endogenous cannabinoid system has not been determined, there is already considerable evidence that the system can be modulated to therapeutic advantage. Indeed, the CBI receptor agonists, nabilone (Cesamet") and A'-THC (dronabinol; Marinol@) are already used clinically to suppress nausea and vomiting provoked by anticancer drugs or to boost the appetite of AIDS patients [30] . There is also evidence that cannabinoid receptor agonists have therapeutic potential for cancer/ post-operative pain relief, for the suppression of muscle spasticity (and pain) associated with mul-tiple sclerosis or spinal injury, for the management of glaucoma, bronchial asthma and inflammatory disorders, and for modulation of immune function [5, . The CBI receptor antagonist, SR141716A, may also have therapeutic potential, for example in reducing memory deficits associated with aging or neurological diseases [5, 30] . Other central disorders that could possibly be treated with cannabinoids include schizophrenia (presumably with drugs that decrease CBI receptor activation; see [30, 32] ), epilepsy and disorders of movement in addition to multiple sclerosis [33] , and neuropathic pain [34, 35] for which improved treatments are urgently required. T h e management of stroke/ ischaemia may be another important application, since the production of anandamide and other acylethanolamides increases dramatically in brain tissue in response to ischaemia or to putative neurotoxins [2, 171 and since the acylethanolamides so produced may have the beneficial effect of reducing calcium release from mitochondria Most attention has so far been paid to the therapeutic potential of established cannabinoid CBI /CB, receptor agonists. However, these have the disadvantage that by producing indiscriminate activation of all cannabinoid receptors they will maximize the incidence of unwanted effects. It is likely that drugs activating the endogenous cannabinoid system indirectly by selectively inhibiting the tissue uptake or metabolism of endogenous cannabinoids so as to increase their levels at cannabinoid receptors will lack this disadvantage. This is because such drugs are unlikely to affect all parts of the endogenous cannabinoid system at one time, producing instead effects only a sites where on-going production of endogenous cannabinoids is occurring. Hence, just as monoamine levels may be enhanced to combat depression, so too modulation of endogenous cannabinoid concentrations at their sites of action may be clinically beneficial. Possible targets at which drugs may act to produce such modulation are transport processes that remove endogenous cannabinoids from the extracellular space and enzymes that catalyse the biosynthesis or metabolic inactivation of these compounds.
The search for drugs that modulate endogenous cannabinoid levels has focused largely on inhibitors of anandamide hydrolysis. Current information about these agents is summarized below.
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Phenylmethanesulphonyl fluoride (PMSF)
This general protease inhibitor is often used in pharmacological assays to protect anandamide from enzymic hydrolysis; it seems to do this in most preparations at concentrations that do not also alter the interaction of anandamide with cannabinoid receptors [ 11. Preparations in which PMSF has been reported to inhibit anandamide hydrolysis include rat brain homogenate (0.9 pM; 200 pM), rat forebrain membranes (12.9 pM; 150 pM), rat brain microsomes (10.5 pM), partially purified pig brain fatty acid amide hydrolase (3-3000 pM), NIRTGZ neuroblastoma and glioma cell membranes (100 pM; 1500 pM), intact NI8TG2 cells (7.8 pM), RBL-2H3 cell membranes (100 pM), mouse uterine microsomes (1-2000 pM) and 1OOOOg pellet fractions of homogenized sea urchin ovaries (250 pM) [2, 11, 161 (Table 1) . Another protease inhibitor reported to inhibit anandamide hydrolysis is diisopropyl fluorophosphate (Table 1) .
Other sulphonyl fluorides
Anandamide hydrolysis in rat brain homogenates is inhibited by certain fatty acid sulphonyl fluorides, some of which have much greater potency than PMSF (Table 1 ). This inhibition is thought to be essentially irreversible [ZO] . Stearylsulphonyl fluoride is of particular interest as it shows marked potency as a fatty acid amide hydrolase inhibitor but lacks significant affinity for cannabinoid CBI receptors. Because stearylsulphonyl fluoride acts irreversibly, this large difference between inhibitory potency and binding potency is especially important as irreversible receptor ligands can, in time, achieve extensive permanent receptor occupancy even when present at quite low concentrations.
Arachidonyl trifluoromethylketone (ATF M K)
This is thought to be a (slowly) reversible transition-state inhibitor of fatty acid amide hydrolase [20] . Preparations in which anandamide hydrolysis has been demonstrated to be markedly inhibited by ATFMK are rat brain homogenate (7.5 pM), partially purified pig brain fatty acid amide hydrolase (0.3-30 pM), NIXTGP cell membranes (10 pM), intact NIXTGZ cells (3.9 pM), RBL-2H3 cell membranes (50 pM), mouse uterine microsomes (1 nM-10 pM) and 10 O O O g pellet fractions of homogenized sea urchin ovaries (100 pM) [2, 11, 16] mityl, myristyl and y-linolenyl trifluoromethylketones, all of which are inhibitory in rat brain homogenate (7.5 pM) [37] . In addition, y-linolenyl trifluoromethylketone (7.8 pM) has a marginal inhibitory effect in NIXTGZ cells [37] and palmityl trifluoromethylketone (50 pM) is inhibitory in RRL-2H3 cell membranes [16] . Trifluoromethylketones other than ATFMK have been reported not to show detectable affinity for CB, receptors at 10 pM [37] .
Methyl arachidonyl fluorophosphonate (MAFP)
This compound has been found to be a potent, irreversible inhibitor of anandamide hydrolysis by rat brain homogenates, intact NIXTGL cells and membrane preparations of NlxTGz and RBL-2H3 cells [ 19, 211 . M M P also produces irreversible inhibition of cytosolic phospholipase A,, albeit at concentrations (ICs,, = -300 nM [38] ) much higher than those at which it inhibits fatty acid amide hydrolase (Table 1 ). The usefulness of MAFP as a modulator of endogenous cannabinoid levels is limited by its ability to undergo covalent binding to CB, receptors [21] (Table 1) as this results in irreversible cannabinoid receptor antagonism [39] . It remains to be established whether the chemical structure of MAFP can be modified to reduce or eliminate its ability to bind to cannabinoid receptors without affecting its ability to inhibit fatty acid amide hydrolase.
Other fatty acid analogues
Koutek et al. [37] found anandamide hydrolysis by rat brain homogenate to be decreased by 7.5 pM stearoyl, palmitoyl, myristoyl, 2-oxyeicosanoyl, 2-oxostearoyl and 2-oxopalmitoyl ethanolamides (15-35% inhibition), by 7.5 pM ethyl 2-oxoeicosanoate (45% inhibition) and by 7.5 pM ethyl 2-oxostearate and ethyl 2-oxopalmitate ( > 80% inhibition). None of these compounds showed detectable affinity for CB, receptors at a concentration of 10 pM. Anandamide hydrolysis is also inhibited in rat brain microsomes and rat cultured cortical astrocytes by oleoyl and linoleoylethanolamide at concentrations of 5 pM and above [40] . More recently, De Petrocellis et al.
[ 191 reported that anandamide hydrolysis can be reversibly inhibited by arachidonoyl diazomethylketone, arachidonoyl chloromethylketone and O-acetylarachidonoyl hydroxamate (Table 1) . Finally, Mechoulam et al. [24] have shown that the putative endogenous sleep factor, oleamide, inhibits anandamide hydrolysis by the 10 000 g particulate fraction of NIxTGz cells at concentrations of 5 pM and above (48% inhibition by 100 pM). Since oleamide is not a CBI receptor ligand [24, 41] , this inhibitory effect on anandamide metabolism presumably underlies its ability to elicit cannabiminietic effects by itself in 7i770 and to potentiate cannabimimetic effects of exogenously added anandamide [24] . These data raise the possibility that effects of oleamide, including sleep induction, may be mediated by anandamide. They also provide evidence that inhibition of anandamide hydrolysis can indeed precipitate significant physiological changes in the whole organism.
The alkylating agents p-hydroxymercuri benzoate (PH M B), p-chloromercuribenzoate (PCMB) and p-brornophenylacyl bromide (PBPB)
An inhibitory effect on anandamide hydrolysis of PHMB and PBPB has been detected in NIXTGL and RBL-2H3 cell membranes (100 ,uM) [2, 16] . PHMB-induced inhibition of anandamide hydrolysis has also been noted in 10 000 g pellet fractions of homogenized sea urchin ovaries (250 pM) [ l l ] . PCMB has been shown to inhibit partially purified pig brain fatty acid amide hydrolase (0.03-1 pM) [2] .
The bromoenol lactone, (E)-6-(bromomethylene)-tetrahydro-
3-( I -naphthalenyl)-2H-pyran-2-one (BTNP)
This irreversible inhibitor of cytosolic Ca2' -independent phospholipase A2 (ICSl, = 0.1 pM) has been found to induce irreversible inhibition of anandamide hydrolysis in microsomal preparations of rat brain (Table 1) . At higher concentrations, BTNP also inhibits anandamide hydrolysis in liver microsomes (Table 1) ; this requirement for higher concentrations presumably reflects a susceptibility of RTNP to metabolism by hepatic enzymes. In addition, BTNP inhibits fatty acid amide hydrolase both in homogenates of cultured neurons and astrocytes obtained from the cerebral cortices of embryonic rats (80% inhibition by 0.5 pM) and in intact rat cortical neurons [14] (Table 1) . It is noteworthy that in a particulate fraction of rat brain tissue, BTNP also inhibits A'-acyltransferase which catalyses the formation of N-arachidonoyl phosphatidylethanolamine, a putative precursor of anandamide (ICsl, = -2 pM) [14] . Other inhibitors of N-acyltransferase (in rat brain tissue) are 
Thimerosal
Inhibition of anandamide hydrolysis by this agent has been detected in rat brain forebrain membranes (Table 1) .
ibuprofen
This non-steroidal anti-inflammatory drug has been found to inhibit anandamide hydrolysis by rat cerebellar homogenates without also interacting with CB, receptors ( Table 1 ). In contrast, naproxen (1 00 pM) arid acetylsalicyclic acid, sulindac, acetaminophen and ketoprofen (300 pM) lacked detectable inhibitory activity [42] . Whether ibuprofen modulates the endogenous cannabinoid system when used clinically remains to be established.
T h e metabolism o f neuronally released anaridamide seems to take place only after neuronal and glial uptake (see above). Consequently, one advance of particular importance has been the development of 5 -( 4 -hydroxyphenyl) arachidonylamide, a drug that inhibits anandamide accumulation in rat neurons and astrocytes in viti-o without also activating CB, receptors or inhibiting anandamide hydrolysis and that enhances receptor-mediated effects of anandamide both in t i t m and in zizn [43] . As to 2-arachidonoyl glycerol, there has been little progress yet in the development of selective inhibitors of its uptake or metabolism. One prototype compound is 2-linoleovl glycerol that has been reported by Di Marzo et al. [44] to decrease the uptake of 2-arachidonovl glycerol by intact RBL-2H3 cells and to inhibit the metabolism of 2-arachidonoyl glycerol to arachidonic acid both by intact RBL-2H3 cells and by particulate fractions of NlxTG2 cells and RBLA-2H3 cells. Di Marzo et al. [44] have also found that 2-linoleoyl glycerol coexists with 2-arachidonoyl glycerol in pancreas arid spleen and does not bind to cannabinoid CB2 receptors [44] . It is noteworthy that the enzymic hydrolysis of 2-arachidonoyl glycerol in NIXTGZ cell preparations has been reported to be only slightly inhibited by 500 pM PMSF and to be unaffected by 200 pM arachidonyl trifluoromethylketone [15] .
In conclusion, although some notable advances have been made, exploration of the therapeutic potential of drugs that can activate the endogenous cannabinoid system indirectly by selectively inhibiting the tissue uptake or metabolism of endogenous cannabinoids is still at an early stage. T o aid the further development of such drugs, research is now needed to characterize more completely the biochemical processes responsible for the biosynthesis and fate of endogenous carinabinoids, to determine whether endogenous cannabinoids are stored or synthesized on demand arid to establish the detailed mechanisms underlying endogenous cannabinoid release. It will also be important to discover why anandamide is normally present at relatively low concentrations, why these concentrations increase so markedly in ischaemia and whether or not anandamide and 2-arachidonoyl glycerol are released from different sites or in response to different stimuli. Another question to be resolved is that of whether modulators of the tissue uptake or metabolism of endogenous cannabinoids can produce any effects that are clinically beneficial and, if so, whether such modulators do indeed have any advantages in the clinic over cannabinoid receptor ligands that act directly.
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